We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Image: Bigstock
Anthera Pharmaceuticals (ANTH) Jumps: Stock Rises 7.9%
Anthera Pharmaceuticals, Inc. (ANTH - Free Report) was a big mover last session, as its shares rose almost 8% on the day. The move came after the company announced an independent expert advisory group gave a positive review of a late-stage clinical trial of its cystic fibrosis drug. This led to far more shares changing hands than in a normal session. This breaks the recent trend of the company, as the stock is now trading above the volatile price range of $3.01 to $3.29 in the past one-month time frame..
None of the estimates for this stock were revised over the past 30 days while the Zacks Consensus Estimate moved lower over the same time frame, suggesting there may be trouble down the road. So make sure to keep an eye on this stock going forward to see if this recent move higher can last.
Anthera Pharmaceuticals currently carries a Zacks Rank #4 (Sell) while its Earnings ESP is positive.
ANTHERA PHARMA Price
ANTHERA PHARMA Price | ANTHERA PHARMA Quote
A better-ranked stock in the med-biomed/gene space is Geron Corporation (GERN - Free Report) , which sports a Zacks Rank #1 (Strong Buy).
Is ANTH going up? Or down? Predict to see what others think: Up or Down
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report >>